Nasometin Control (Mometasone Furoate)

Mometasone furoate, the active ingredient in Nasometin Control, is a glucocorticoid presented as a nasal spray for nasal use. It is indicated for the treatment of allergic rhinitis in both adults and children, helping to relieve nasal congestion, itching, and sneezing associated with the condition.

GNH USA supplies Nasometin Control as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution through its experienced network.

Nasometin Control, containing mometasone furoate, is used to manage inflammatory conditions of the nasal passages.

Allergic rhinitis (seasonal): Reduces nasal congestion, sneezing, and itching during pollen seasons. Allergic rhinitis (perennial): Controls year‑round nasal inflammation and symptom severity. Allergic rhinitis (mixed): Improves overall nasal airflow and lessens mucosal swelling. Nasal allergy symptoms: Provides relief from itching, rhinorrhea, and post‑nasal drip associated with allergic triggers.

Mometasone furoate may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation or burning. - Headache. - Epistaxis (nosebleeds). - Throat irritation.

Serious or Rare Side Effects: - Nasal septal perforation. - Adrenal suppression with prolonged use. - Severe allergic reaction (anaphylaxis).

When using Nasometin Control, consider the following precautions.

Assess for active nasal infection before initiating therapy. Use the lowest effective dose for the shortest duration needed. Avoid prolonged continuous use beyond recommended period. Monitor for signs of adrenal insufficiency during long‑term treatment. Do not use in children under 2 years of age unless directed by a specialist. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Potential drug interactions should be reviewed before prescribing Nasometin Control.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase systemic exposure. - Concurrent systemic corticosteroids can amplify glucocorticoid effects.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., itraconazole) may modestly raise mometasone levels. - HIV protease inhibitors (e.g., ritonavir) may affect metabolism. - Oral contraceptives may have reduced efficacy with systemic corticosteroid exposure.